Anfield Capital Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-312
Closed -$17.8K 76
2022
Q4
$17.8K Sell
312
-820
-72% -$42K 0.01% 79
2022
Q3
$45K Buy
1,132
+39
+4% +$1.72K 0.02% 82
2022
Q2
$48K Buy
1,093
+156
+17% +$6.75K 0.02% 82
2022
Q1
$37K Buy
937
+670
+251% +$23.9K 0.01% 84
2021
Q4
$11K Buy
267
+246
+1,171% +$9.18K ﹤0.01% 91
2021
Q3
$1K Buy
+21
New +$878 ﹤0.01% 113

Other funds holding HALO

Anfield Capital Management's HALO Position: Q1 2023 in Review

Anfield Capital Management sold out of Halozyme (HALO) in Q1 2023, closing a stake of 312 shares — an estimated $17.8K sold.

Anfield Capital Management first reported a position in HALO in Q3 2021 and held it in 6 quarters. The position peaked at $48K in Q2 2022. 386 funds tracked by Wall St. Rank hold HALO as of Q1 2023.

  • Anfield Capital Management reported no remaining Halozyme position as of Q1 2023 after selling out during the quarter.
  • Anfield Capital Management sold 312 Halozyme shares in Q1 2023, an estimated $17.8K.
  • Anfield Capital Management first reported a position in Halozyme in Q3 2021 and held it in 6 quarters.
  • Anfield Capital Management's Halozyme position peaked at $48K in Q2 2022.
  • 386 funds tracked by Wall St. Rank held Halozyme as of Q1 2023.

Based on Anfield Capital Management's 13F filing for Q1 2023, filed 4 May 2023.